As part of a commitment to share at least 5% of the national vaccine supply with its development partners, the first doses given by Portugal via COVAX have reached Senegal.
The 298,700 doses of the AstraZeneca vaccine donated by Portugal arrived in Dakar on October 2, 2021, and will be officially handed over to the Senegalese authorities on October 18, during a ceremony that will take place at the Ministry of Health and Action Social Affairs of Senegal, with the participation of HE the Minister of Health and Social Action of Senegal, Abdoulaye Diouf Sarr, and HE the Secretary of State for Foreign Affairs and Cooperation of Portugal, Francisco André.
The Chairman of the Board of Directors of Gavi, Professor José Manuel Barroso: “I am so proud that my homeland, Portugal, is getting involved and contributing to the cause of equitable access by donating doses through COVAX. Gavi is very happy to see these first doses of the AstraZeneca vaccine donated by the Portuguese government reaching the African continent. “
Gavi CEO Dr Seth Berkley: “Portugal has shown increasing leadership in global health, funding routine immunization programs through Gavi during the period 2021-2025. and 1.5 million euros from the Portuguese private sector, this donation of doses shows the continued commitment of the Portuguese people to equitable access to vaccines. “
Geneva, October 18, 2021 – The first 298,700 doses of the AstraZeneca vaccine donated by Portugal to COVAX arrived in Senegal on October 2, 2021 and will be officially delivered during a ceremony to be held today in Dakar, in the presence of HE the Minister of Health and Social Affairs Action of Senegal, Abdoulaye Diouf Sarr, and the Secretary of State for Foreign Affairs and Cooperation of Portugal, Francisco André.
This Portuguese donation is part of a commitment to donate at least 5% of its national supply to cooperation partners, under which more than 1.2 million doses of COVID-19 vaccines have already been delivered bilaterally to Portuguese-speaking countries of Africa and Timor-Leste. In addition, funding of EUR 678,125 was provided to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC) by the Portuguese government and EUR 1.5 million from the Portuguese private sector.
Portugal’s commitment to global immunization has grown in recent years, with a funding pledge made at the World Vaccine Summit in June 2020 by the Portuguese Minister of Health, who announced that Portugal would contribute for the first time to the Alliance funding Gavi core programs. in 2021-2025, with a focus on improving access and quality of primary health care and reducing child mortality.
“I am so proud that my homeland, Portugal, is getting involved and contributing to the cause of equitable access by donating doses through COVAX,” said Gavi board chairman Professor José Manuel Barroso. “Gavi is very happy to see these first doses of the AstraZeneca vaccine donated by the Portuguese government reach the African continent.”
“Portugal has shown growing leadership in global health, funding routine immunization programs through Gavi during the period 2021-2025,” said Gavi CEO Dr Seth Berkley . “In addition to the funding of EUR 678,125 already provided to the Gavi COVAX Advance Market Commitment by the Portuguese government and EUR 1.5 million from the Portuguese private sector, this dose donation shows the continued commitment of the Portuguese people in favor of ” equitable access to vaccines. “
Donating through COVAX helps increase immunization coverage, ensures that no dose is wasted, and helps end the acute phase of the pandemic. Dose donation via COVAX is possible through tripartite agreements between Gavi, manufacturers and donor countries. Shipments to countries will be activated by delivery partners COVAX, UNICEF and the World Health Organization (WHO).
Over 600 million doses have already been pledged to COVAX by a number of countries in response to short-term supply challenges and the rise of new variants. By working with donor governments to operationalize a growing number of dose-sharing commitments, COVAX expects to see more deliveries of donated doses in the weeks and months to come.
Notes to Editors
COVAX, the vaccine pillar of the COVID-19 Tool Access Accelerator (ACT), is co-led by CEPI, Gavi and WHO – working in partnership with vaccine manufacturers in developed and developing countries, the UNICEF, PAHO, the World Bank and others. It is the only global initiative that works with governments and manufacturers to ensure that COVID-19 vaccines are available worldwide for high-income and low-income countries.
Gavi’s role in COVAX
Gavi leads large-scale procurement and delivery for COVAX: design and management of the COVAX facility and AMC Gavi COVAX and collaboration with its traditional Alliance partners, UNICEF and WHO, as well as governments, on country preparation and delivery. As part of this role, Gavi hosts the COVAX Facility Office to coordinate the operation and governance of the mechanism as a whole, maintains financial and legal relationships with 193 participants of the Facility and manages the COVAX Facility transaction portfolio. : negotiate advance purchase agreements with promising vaccine manufacturers to secure doses on behalf of all participants of the COVAX platform. Gavi is also coordinating the design, operationalization and fundraising for the Gavi COVAX AMC, the mechanism that provides access to donor-funded doses of vaccine to 92 low-income economies. As part of this work, Gavi provides funding and oversight for UNICEF vaccine procurement and delivery to all AMC participants – operationalizing advance purchase agreements between Gavi and manufacturers. – as well as support to partners and governments in preparation and delivery. This includes tailor-made support to governments, UNICEF, WHO and other partners for cold chain equipment, technical assistance, syringes, vehicles and other aspects of extremely complex logistics operation for delivery. Gavi has also co-designed, fundraised and supported the operationalization of the AMC No-Fault Compensation Mechanism as well as the COVAX Humanitarian Buffer.
About Gavi, the Vaccine Alliance
Gavi, the Vaccine Alliance is a public-private partnership that helps immunize half of the world’s children against some of the world’s deadliest diseases. Since its inception in 2000, Gavi has helped immunize an entire generation – over 888 million children – and averted more than 15 million future deaths, helping to halve child mortality in 73 low-income countries. Gavi also plays a key role in improving global health security by supporting health systems and funding global stocks of vaccines against Ebola, cholera, meningitis and yellow fever. After two decades of progress, Gavi is now focused on protecting the next generation and reaching the unvaccinated children still left behind, using innovative financing and the latest technology – from drones to biometrics – to save millions. more lives, prevent epidemics before they can spread and help countries on the road to self-sufficiency. Learn more at www.gavi.org and connect with us on Facebook and Twitter.
Gavi is the co-organizer of COVAX, the vaccine pillar of the COVID-19 Tool Access Accelerator (ACT), with the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO). In his role, Gavi focuses on procurement and delivery for COVAX: coordinating the design, implementation and administration of the COVAX facility and AMC Gavi COVAX and working with its partners in the COVAX. Alliance, UNICEF and WHO, as well as with governments, on country preparedness and delivery.
The Vaccine Alliance brings together developing countries and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill & Melinda Gates Foundation and other private sector partners. Check out the full list of donor governments and other leading organizations funding Gavi’s work here.
Evan o’connell +41 79 682 18 95 [email protected]
Iryna Mazur +41 79 429 3671 [email protected]
Meg sharafudeen +41 79 711 55 54 [email protected]
Laura Chevlin + 41 79 529 92 87 [email protected]
Cirũ Kariũki +41 79 913 94 41 [email protected]